|Bid||152.52 x 1000|
|Ask||153.42 x 1000|
|Day's range||152.75 - 155.45|
|52-week range||105.56 - 175.91|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||21.97|
|Forward dividend & yield||5.64 (4.08%)|
|Ex-dividend date||14 Apr 2022|
|1y target est||N/A|
In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.
AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.